CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-10 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −158,194 | $40.44 | $6.4M | 840,960 |
| 2026-11-10 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −29,749 | $41.00 | $1.2M | 811,211 |
| 2026-11-03 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.31 | $7.3M | 999,154 |
| 2026-10-28 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.59 | $7.3M | 1,199,154 |
| 2026-10-20 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −185,856 | $35.09 | $6.5M | 1,413,298 |
| 2026-10-20 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −14,144 | $35.42 | $501K | 1,399,154 |
| 2026-09-30 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,799,154 |
| 2026-09-30 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.62 | $7.3M | 1,599,154 |
| 2026-09-30 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 3,644,834 | ||
| 2026-08-28 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,799,154 |
| 2026-08-28 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −166,182 | $35.63 | $5.9M | 1,632,972 |
| 2026-08-28 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −33,818 | $36.44 | $1.2M | 1,599,154 |
| 2026-08-28 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 3,844,834 | ||
| 2026-08-20 | Venker Eric President & Immunovant CEO | Shares withheld for taxes | −13,909 | $36.84 | $512K | 1,599,154 |
| 2026-07-27 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,813,063 |
| 2026-07-27 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $34.95 | $7.0M | 1,613,063 |
| 2026-07-27 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 4,044,834 | ||
| 2026-06-24 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,813,063 |
| 2026-06-24 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −153,766 | $33.05 | $5.1M | 1,659,297 |
| 2026-06-24 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −46,234 | $33.51 | $1.5M | 1,613,063 |
Page 1 of 8 · 160 trades